成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Cytoskeleton
  3. Arp2/3 Complex
  4. Cytochalasin B

Cytochalasin B  (Synonyms: 細(xì)胞松弛素B; Phomin)

目錄號: HY-16928 純度: 99.78%
COA 產(chǎn)品使用指南 技術(shù)支持

Cytochalasin B 是一種能透過細(xì)胞的真菌毒素，能夠與肌動蛋白絲的有刺端結(jié)合，擾亂肌動蛋白聚合物的形成，對 F-actin 的 Kd 值為 1.4-2.2 nM。Cytochalasin B 抑制細(xì)胞遷移。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Cytochalasin B Chemical Structure

Cytochalasin B Chemical Structure

CAS No. : 14930-96-2

1.  客戶無需承擔(dān)相應(yīng)的運輸費用。

2.  同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥3590
In-stock
1 mg ￥950
In-stock
5 mg ￥4000
In-stock
10 mg 現(xiàn)貨 詢價
50 mg   詢價  
100 mg   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Cytochalasin B:

MCE 顧客使用本產(chǎn)品發(fā)表的 31 篇科研文獻(xiàn)

IF
WB

    Cytochalasin B purchased from MCE. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583.  [Abstract]

    Expression of CTC cluster-related (plakoglobin and CD44) and EMT-related (vimentin and E-cadherin, 4 days) proteins in LNCaP cells grown on different substrates after treatment with different inhibitors (Cytoskeleton B (CB), Nocodazole (NO), PF-573288 (PF), Y-27632 (Y), and (-)-Blebbistatin ((-) Bl)).

    Cytochalasin B purchased from MCE. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583.  [Abstract]

    Immunofluorescence imaging of LNCaP cells treated with the Cytoskeleton B (CB), Nocodazole (NO), PF-573288 (PF), Y-27632 (Y), and (-)-Blebbistatin ( (-) Bl). After the cells are cultured on different substrates for 3 days, inhibitors are added and incubated for 24 h.

    • 生物活性

    • 實驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Cytochalasin B is a cell-permeable mycotoxin binding to the barbed end of actin filaments, disrupting the formation of actin polymers, with Kd value of 1.4-2.2 nM for F-actin. Cytochalasin B blocks cell migration.

    IC50 & Target

    Kd: 2.2 nM (F-actin, with Mg2+), 1.4 nM (F-actin, with Mg2+/K+)[1]
    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    2.13 μM
    Compound: 5
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    CHO IC50
    0.26 μg/mL
    Compound: Cytochalasin B
    Cytotoxicity against CHO cells transfected with ICAM1 by MTT assay
    Cytotoxicity against CHO cells transfected with ICAM1 by MTT assay
    		[PMID: 15165136]
    HCT-116 IC50
    12 μM
    Compound: 8
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34846891]
    HCT-15 IC50
    1.94 μM
    Compound: 5
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    HEK293 IC50
    > 10 μM
    Compound: 5311281
    Inhibition of the Glucose Transporter (GLUT2, SLC2A2) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A2 WT-OE cells
    Inhibition of the Glucose Transporter (GLUT2, SLC2A2) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A2 WT-OE cells
    		10.5281/zenodo.7360664
    HEK293 IC50
    3.9 μM
    Compound: 5311281
    Inhibition of the Glucose Transporter (GLUT3, SLC2A3) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A3 WT-OE cells
    Inhibition of the Glucose Transporter (GLUT3, SLC2A3) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A3 WT-OE cells
    		10.5281/zenodo.7360656
    HEK293 IC50
    3.9 μM
    Compound: 5311281
    Inhibition of the Glucose Transporter (GLUT4, SLC2A4) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A4 WT-OE cells
    Inhibition of the Glucose Transporter (GLUT4, SLC2A4) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A4 WT-OE cells
    		10.5281/zenodo.7360638
    HEK293 IC50
    4.1 μM
    Compound: 5311281
    Inhibition of the Glucose Transporter (GLUT1, SLC2A1) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A1 WT-OE cells
    Inhibition of the Glucose Transporter (GLUT1, SLC2A1) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A1 WT-OE cells
    		10.5281/zenodo.7360676
    HeLa IC50
    0.25 μg/mL
    Compound: Cytochalasin B
    Inhibition of LFA1/ICAM1-mediated CFSE-labeled TPA-stimulated human HL60 cell adhesion to ICAM1 expressing human HeLa cells after 45 mins by fluorescence analysis
    Inhibition of LFA1/ICAM1-mediated CFSE-labeled TPA-stimulated human HL60 cell adhesion to ICAM1 expressing human HeLa cells after 45 mins by fluorescence analysis
    		[PMID: 11374943]
    HeLa IC50
    5.5 μg/mL
    Compound: cytochalasin B
    Inhibition of LFA1:CD11a/CD18/ICAM1-mediated human HL60 cell adhesion to human HeLa cells expressing ICAM1 by fluorescence analysis
    Inhibition of LFA1:CD11a/CD18/ICAM1-mediated human HL60 cell adhesion to human HeLa cells expressing ICAM1 by fluorescence analysis
    		[PMID: 12880315]
    HeLa IC50
    7.9 μM
    Compound: 5
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    HepG2 IC50
    9.5 μM
    Compound: 8
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34846891]
    HL-60 IC50
    > 30 μg/mL
    Compound: cytochalasin B
    Cytotoxicity against human HL60 cells by XTT assay
    Cytotoxicity against human HL60 cells by XTT assay
    		[PMID: 12880315]
    HL-60 IC50
    > 30 μg/mL
    Compound: Cytochalasin B
    Cytotoxicity against human HL60 cells after 7 days by XTT/PMS assay
    Cytotoxicity against human HL60 cells after 7 days by XTT/PMS assay
    		[PMID: 11374943]
    HL-60 IC50
    40 μg/mL
    Compound: Cytochalasin B
    Cytotoxicity against human HL60 cells by XTT assay
    Cytotoxicity against human HL60 cells by XTT assay
    		[PMID: 15165136]
    MCF7 IC50
    5.2 μM
    Compound: 8
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34846891]
    RAW264.7 IC50
    5.6 μg/mL
    Compound: Cytochalasin B
    Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs
    Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs
    		[PMID: 15165136]
    RAW264.7 IC50
    6.5 μg/mL
    Compound: Cytochalasin B
    Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay
    Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay
    		[PMID: 15165136]
    SK-MEL-2 IC50
    0.67 μM
    Compound: 5
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    SK-OV-3 IC50
    0.46 μM
    Compound: 5
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    XF498 IC50
    2.36 μM
    Compound: 5
    Cytotoxicity against human XF498 cells after 48 hrs by SRB assay
    Cytotoxicity against human XF498 cells after 48 hrs by SRB assay
    		[PMID: 22483395]
    體外研究
    (In Vitro)

    Cytochalasin B 是一種可穿透細(xì)胞的霉菌毒素，可與肌動蛋白絲的倒鉤端結(jié)合，抑制肌動蛋白絲的伸長和縮短，在 MgCl2（2 mM）或 MgCl2（2 mM）加 KCl 存在下，對 F-肌動蛋白的 Kds 分別為 2.2 nM 和 1.4 nM[1]。Cytochalasin B（0.1-10 μM）對多種鼠癌細(xì)胞系有抑制作用，處理3小時后，IC50s分別為2.56 μM（M109c）、10.46 μM（B16BL6）、105.5 μM（P388/ADR）、51.9 μM（P388/S），IC80 分別為12.23 μM（M109c）、44.86 μM（B16BL6）、188.4 μM（P388/ADR）、84.1 μM（P388/S），IC50s分別為0.25 μM（M109c）、0.37 μM（B16F10）、0.87 μM（B16BL6）處理 4 天后，IC80 分別為 0.75 μM (M109c)、1.21 μM (B16F10)、10.41 μM (B16BL6)[2]。Cytochalasin B (6 μM) 可增加肌原纖維碎裂指數(shù) (MFI)，這是由于肌原纖維蛋白強烈斷裂成短片段所致。Cytochalasin B 還可加速肌動蛋白絲的斷裂。此外，Cytochalasin B 可加速 F- 肌動蛋白向 G- 肌動蛋白的轉(zhuǎn)化，降低 F- 肌動蛋白的含量，并顯著增加死后處理過程中的 G- 肌動蛋白條帶[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    Cytochalasin B（10、25、50 mg/kg，腹腔注射）劑量依賴性地延長了患有 P388/ADR 白血病的 Balb/c 小鼠的預(yù)期壽命。50 mg/kg 的 Cytochalasin B 可使多藥耐藥 P388/ADR 群的長期存活率提高 10%，使藥物敏感的 P388/S 群的長期存活率提高 40%[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    479.61

    Formula

    C29H37NO5
    CAS 號
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    細(xì)胞松弛素B；松胞菌素B
    結(jié)構(gòu)分類
    初始來源

    Mould
    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性數(shù)據(jù)
    細(xì)胞實驗： 

    DMSO 中的溶解度 : 83.33 mg/mL (173.75 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    Ethanol 中的溶解度 : 25 mg/mL (52.13 mM; 超聲助溶)

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 2.0850 mL 10.4251 mL 20.8503 mL
    5 mM 0.4170 mL 2.0850 mL 4.1701 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% EtOH    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (5.21 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 EtOH 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% EtOH    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (5.21 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 EtOH 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： 0.5% CMC-Na/0.5% Tween-80 in Saline water

      Solubility: 5 mg/mL (10.43 mM); Suspened solution; 超聲助溶

    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.84%

    參考文獻(xiàn)
    Cell Assay
    [2]

    The attached cell lines M109c, B16BL6, and B16F10 are seeded at 1 to 4?×?104 cells/mL in 2 mL volumes in 24-well culture plates 1 day prior to treatment with Cytochalasin B. The suspension culture of P388/ADR cells is seeded at 5?×?104 cells/mL and allowed to grow overnight before Cytochalasin B treatment. Cells are treated with Cytochalasin B for 3 h, as well as 2, 3, or 4 days. In the case of continuous exposure for 2, 3, or 4 days, attached cells are trypsinized and counted with a hemacytometer. Leukemia cell suspensions are counted with a Coulter Counter. In the case of short-term exposure, cells are washed twice with fresh medium, then trypsinized (except for P388/ADR cells), reseeded, and allowed to regrow for 3 days, at which time they are counted. Growth results are calculated as the number of cells generated above the seeding density compared to the untreated control cells and graphically presented as percent of control increase[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [2]

    Mice[2]
    For chemotherapy testing, Balb/c mice under isoflurane anesthesia are challenged with 2?×?105 trypan blue negative P388/S or P388/ADR cells subcutaneously (s.c.) in a volume of 200 μL. Untreated mice are kept in order to determine the lethality of the challenge without chemotherapeutic intervention. Long-term survival is defined as challenged mice that survive the duration of the observation period. Cytochalasins B and D are prepared in suspension form in 2 % carboxymethyl cellulose 1 % tween 20 (CMC/Tw) for intraperitoneal (i.p.) administration. The congeners or the vehicle are administered to leukemia-challenged mice on Days 1-8 following the initial challenge[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻(xiàn)

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 2.0850 mL 10.4251 mL 20.8503 mL 52.1257 mL
    5 mM 0.4170 mL 2.0850 mL 4.1701 mL 10.4251 mL
    10 mM 0.2085 mL 1.0425 mL 2.0850 mL 5.2126 mL
    15 mM 0.1390 mL 0.6950 mL 1.3900 mL 3.4750 mL
    20 mM 0.1043 mL 0.5213 mL 1.0425 mL 2.6063 mL
    25 mM 0.0834 mL 0.4170 mL 0.8340 mL 2.0850 mL
    30 mM 0.0695 mL 0.3475 mL 0.6950 mL 1.7375 mL
    40 mM 0.0521 mL 0.2606 mL 0.5213 mL 1.3031 mL
    50 mM 0.0417 mL 0.2085 mL 0.4170 mL 1.0425 mL
    DMSO 60 mM 0.0348 mL 0.1738 mL 0.3475 mL 0.8688 mL
    80 mM 0.0261 mL 0.1303 mL 0.2606 mL 0.6516 mL
    100 mM 0.0209 mL 0.1043 mL 0.2085 mL 0.5213 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Cytochalasin B
    目錄號：
    HY-16928
    需求量：